Skip to main content
. 2018 Sep 7;4(2):e000692. doi: 10.1136/rmdopen-2018-000692

Figure 3.

Figure 3

DAS28-CRP LSM change from baseline after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to cDMARDs or MTX. The treatment-by-cDMARD use interaction p-value for DAS28-CRP was 0.037. **p<0.01, ***p<0.001, both versus PBO. cDMARD, conventional disease-modifying antirheumatic drugs; DAS28-CRP, 28-joint Disease Activity Score using C-reactive protein; IXEQ4W, ixekizumab every 4 weeks; IXEQ2W, ixekizumab every 2 weeks; LSM, least squares mean; MTX, methotrexate; n, number of patients; PBO, placebo; SE, standard error.